Study of Alisertib (MLN8237) in Adults With Aggressive Non-Hodgkin's Lymphoma
Status:
Completed
Trial end date:
2013-02-13
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the anti-tumor activity of alisertib (MLN8237) in
participants with relapsed or refractory non-hodgkin's lymphoma.